Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
Alimentary Pharmacology & Therapeutics · 2026-05 · 63 (10) · 1439-1440
DOI: 10.1111/apt.70610 ↗At a glance
Leserbrief in Alimentary Pharmacology & Therapeutics, published online on 2026-03-07. Written by Yu-Sheng Lin and 2 co-authors. Institution: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan. 9 references.
Abstract (original language)
Intet abstract tilgængeligt.
Subjects
Author keywords
Authors and institutions
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
- Department of Post-Baccalaureate Medicine, College of Medicine, Chung Hsing University, Taichung, Taiwan.
- Cardiovascular Center, Taichung Veterans General Hospital, Taichung, Taiwan.
- Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan.
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
ORCID profiles: Teng-Yu Lee
Cite
APA
Lin, Y. S., Chen, Y. Y., & Lee, T. Y. (2026). Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply. Alimentary Pharmacology & Therapeutics, 63(10), 1439-1440. https://doi.org/10.1111/apt.70610
Vancouver
Lin YS, Chen YY, Lee TY. Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply. Alimentary Pharmacology & Therapeutics. 2026;63(10):1439-1440. doi:10.1111/apt.70610
BibTeX
@article{Lin2026,
author = {Lin, Yu-Sheng and Chen, Yun-Yu and Lee, Teng-Yu},
title = {Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {63},
number = {10},
pages = {1439--1440},
doi = {10.1111/apt.70610}
}
EUVIMED